Canna Law Blog

MARCH 4, 2020

Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). Recently, the decriminalization of psilocybin (by various cities) has been in the news as an emerging medicine.

Therapy 104

Therapy Legalization Chronic Pain DEA 104

Cannabis Law Report

JULY 9, 2021

Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , Clinical Trial ID NCT03866174, available at [link].

Law 81

Law Therapy Clinical Trials Research and Development 81

The Cannigma

MAY 1, 2023

2 3 As clinical trials around the world proceeded in the late 1960s and 1970s, patients began reporting difficulty tolerating ketamine’s unpleasant hallucinogenic and dissociative properties. Ketamine was approved by the FDA in 1970 and was immediately put to use as an important tool for war medics in the Vietnam War.

Blood Pressure 80

Blood Pressure Chronic Pain Research and Development Clinical Trials 80

Veriheal

AUGUST 31, 2020

However, social and economic barriers like racial stereotypes and lack of access to care centers have historically barred Hispanic community members from seeking medical cannabis and participating in clinical trials. Supply chains are disrupted as a result, and consumers grow fearful of buying hemp.

Research and Development 119

Research and Development Education Agriculture Patients 119

Canna Law Blog

MARCH 4, 2020

Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). The post The Ketamine Clinic Craze: Legalities and Possibilities appeared first on Harris Bricken.

Legalization 55

Legalization Therapy Chronic Pain DEA 55

Veriheal

NOVEMBER 7, 2024

The Drug Enforcement Administration (DEA) announced in August that a hearing regarding the reclassification decision will take place on December 2, 2024, before an administrative law judge. Then, the DEA will review the report and draft a final ruling, factoring in all relevant information submitted during the public comment period.

DEA 97

DEA Policy Chronic Pain Marijuana 97